Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.

被引：0
|
作者：
Ozcan, Muhit
Lee, Seung Tae
Mensah, Felix
Modi, Dipenkumar
Fossa, Alexander
Kim, Won Seog
Paszkiewicz-Kozik, Ewa
Sawalha, Yazeed
Sevindik, Omur Gokmen
Norasetthada, Lalita
Santoro, Armando
Pathiraja, Kumudu
Chakraborty, Samhita
Marinello, Patricia
Lavie, David
机构：
[1] Ankara Univ, Sch Med, Ankara, Turkiye
[2] Univ Maryland Marlene, Baltimore, MD USA
[3] Stewart Green Ebaum Comprehens Canc Ctr, Baltimore, MD USA
[4] Franciscan Hlth, Indiana Blood & & Marrow Transplantat, Indianapolis, IN USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Oslo Univ Hosp, Oslo, Norway
[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[8] Maria Sklodowska Curie Natl Inst Oncol, Warsaw, Poland
[9] Ohio State Univ, James Canc Hosp & Solove Res Inst, Columbus, OH USA
[10] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye
[11] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand
[12] Humanitas Univ, Pieve & IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy
[13] Merck Co Inc, Rahway, NJ USA
[14] Hadassah Med Ctr, Jerusalem, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7531
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)
    Lenz, Georg
    Rutherford, Sarah C.
    Davies, Andrew
    Zinzani, Pier Luigi
    Salles, Gilles
    Hasskarl, Jens
    Margunato-Debay, Sandra
    Rodrigues, Filipe
    Nientker, Lisette
    Balradj, Janita
    Alleman, Cathelijne
    BLOOD, 2018, 132
  • [22] Patient, caregiver, and physician preferences for treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Vukcevic, Mirko
    Yung, Mallory
    Khan, Maliha
    Schnell, Frederick Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18710 - E18710
  • [23] Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective
    Moertl, Bernhard
    Dreyling, Martin
    Schmidtl, Christian
    Hoster, Eva
    Schoel, Wolfgang
    V. Bergwelt-Baildon, Michael
    Berger, Karin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 474 - 482
  • [24] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
  • [25] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [26] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Balari, Anna Sureda
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study
    Paskiewicz-Kozik, Ewa
    Glimelius, Ingrid
    Moreira, Claudia
    Garrido, Marcelo
    Ernst, Daniel
    Jurczak, Wojciech
    Merryman, Reid
    Kim, Won Seog
    Ozcan, Muhit
    Santoro, Armando
    Sawalha, Yazeed
    Berkovits, Alejandro
    Ren, Yixin
    Ogbu, Uzor
    Yusuf, Rushdia
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S483 - S484
  • [28] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [29] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    Van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Marie Jose
    Schuster, Stephen J.
    Salles, Gilles Andre
    Maziarz, Richard Thomas
    Anak, Oezlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    BLOOD, 2017, 130
  • [30] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Maakaron, Joseph
    Asch, Adam S.
    Popplewell, Leslie L.
    Collins, Graham P.
    Flinn, Ian W.
    Ghosh, Nilanjan
    Keane, Colin
    Ku, Matthew
    Mehta, Amitkumar
    Roschewski, Mark
    O'Hear, Carol
    Ren, Xuehan
    Villa, Bertha
    Lal, Indu
    Smith, Sonali M.
    Advani, Ranjana H.
    BLOOD, 2022, 140 : 3728 - 3730
12345